Positive Response to One-Year Treatment With Burosumab in Pediatric Patients With X-Linked Hypophosphatemia

Positive Response to One-Year Treatment With Burosumab in Pediatric Patients With X-Linked Hypophosphatemia

X-linked hypophosphatemia (XLH) causes significant burden in pediatric patients in spite of maintained treatment with phosphate supplements and vitamin D derivatives. Administration of burosumab has shown promising results in clinical trial but studies assessing its effect in the everyday practice a...

Full description

Bibliographic Details
Main Authors: Silvia Martín Ramos, Marta Gil-Calvo, Virginia Roldán, Ana Castellano Martínez, Fernando Santos
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-02-01
Series:Frontiers in Pediatrics
Subjects:
X-linked hypophosphatemia (XLH)
rickets
burosumab
FGF23
hypophosphatemia
vitamin D
Online Access:https://www.frontiersin.org/article/10.3389/fped.2020.00048/full

Internet

https://www.frontiersin.org/article/10.3389/fped.2020.00048/full

Similar Items